[go: up one dir, main page]

HK1200190A1 - 靶向的酶化合物及其應用 - Google Patents

靶向的酶化合物及其應用

Info

Publication number
HK1200190A1
HK1200190A1 HK15100521.1A HK15100521A HK1200190A1 HK 1200190 A1 HK1200190 A1 HK 1200190A1 HK 15100521 A HK15100521 A HK 15100521A HK 1200190 A1 HK1200190 A1 HK 1200190A1
Authority
HK
Hong Kong
Prior art keywords
targeted enzyme
enzyme compounds
compounds
targeted
enzyme
Prior art date
Application number
HK15100521.1A
Other languages
English (en)
Inventor
多米尼克.波依溫
讓-保羅.卡斯泰恩
米歇爾.德默勒
薩斯米塔.塔里帕西
讓-克里斯托夫.柯里
西蒙.洛德-杜富爾
Original Assignee
Angiochem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angiochem Inc filed Critical Angiochem Inc
Publication of HK1200190A1 publication Critical patent/HK1200190A1/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/33Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y301/00Hydrolases acting on ester bonds (3.1)
    • C12Y301/06Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06013Iduronate-2-sulfatase (3.1.6.13)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
HK15100521.1A 2011-12-01 2015-01-16 靶向的酶化合物及其應用 HK1200190A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161565764P 2011-12-01 2011-12-01
US201261596516P 2012-02-08 2012-02-08
PCT/CA2012/050865 WO2013078562A2 (en) 2011-12-01 2012-11-30 Targeted enzyme compounds and uses thereof

Publications (1)

Publication Number Publication Date
HK1200190A1 true HK1200190A1 (zh) 2015-07-31

Family

ID=48536182

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15100521.1A HK1200190A1 (zh) 2011-12-01 2015-01-16 靶向的酶化合物及其應用

Country Status (10)

Country Link
US (1) US20140335163A1 (zh)
EP (1) EP2785837A4 (zh)
JP (1) JP2015500800A (zh)
CN (1) CN104136606A (zh)
AU (1) AU2012344700A1 (zh)
BR (1) BR112014013250A2 (zh)
CA (1) CA2857548A1 (zh)
HK (1) HK1200190A1 (zh)
RU (1) RU2014126482A (zh)
WO (1) WO2013078562A2 (zh)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2516056C (en) 2003-01-06 2012-05-29 Angiochem Inc. Aprotinin and analogs as carriers across the blood-brain barrier
SI2233156T1 (sl) 2005-07-15 2013-09-30 Angiochem Inc. Uporaba polipeptidov aprotinina kot nosilce v farmacevtskih konjugatih
US9365634B2 (en) 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
EP2346896A4 (en) 2008-10-15 2014-06-25 Angiochem Inc CONJUGATES OF ETOPOSIDE AND DOXORUBICIN FOR THE ADMINISTRATION OF MEDICAMENTS
WO2010043047A1 (en) 2008-10-15 2010-04-22 Angiochem Inc. Conjugates of glp-1 agonists and uses thereof
EP2373789A4 (en) 2008-12-17 2012-08-29 Angiochem Inc MEMBRANTYP-1 MATRIX METALLOPROTEINASE INHIBITORS AND THEIR USE
EP2421562B1 (en) 2009-04-20 2019-03-13 Angiochem Inc. Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog
IN2012DN00248A (zh) 2009-07-02 2015-05-01 Angiochem Inc
RU2014126484A (ru) * 2011-12-01 2016-02-10 Ангиочем Инк. Нацеленные соединения лизосомальных ферментов
WO2013181697A1 (en) * 2012-06-05 2013-12-12 The University Of Melbourne Bicyclo[6.1.0]non-4-yne compounds suitable for use as linkers in biological applications
MX2014015551A (es) * 2012-06-15 2016-09-19 Angiochem Inc Compuestos iduronidasa apuntados.
US9687561B2 (en) 2012-08-14 2017-06-27 Angiochem Inc. Peptide-dendrimer conjugates and uses thereof
CN104955946A (zh) * 2012-11-30 2015-09-30 安吉奥开米公司 靶向的艾杜糖醛酸-2-硫酸酯酶化合物
GB201300707D0 (en) * 2013-01-15 2013-02-27 Novartis Ag Compounds and processes
WO2014194427A1 (en) * 2013-06-06 2014-12-11 Angiochem Inc. Targeted iduronate-2-sulfatase fusion proteins
WO2018094035A2 (en) 2016-11-16 2018-05-24 Purdue Research Foundation Ligand ionophore conjugates
ES2826827T3 (es) 2015-06-15 2021-05-19 Angiochem Inc Métodos para el tratamiento de carcinomatosis leptomeníngea
KR102368068B1 (ko) 2015-08-24 2022-02-25 삼성전자주식회사 반도체 소자 제조용 조성물 및 이를 이용하는 반도체 소자의 제조 방법
GB201603296D0 (en) 2016-02-25 2016-04-13 Ucl Business Plc Chemotactic,drug-containing polymersomes
GB201604553D0 (en) 2016-03-17 2016-05-04 Ucl Business Plc Fumarate polymersomes
CN109641971B (zh) * 2016-08-25 2023-04-04 Jcr制药股份有限公司 抗体融合蛋白的制造方法
GB201701968D0 (en) 2017-02-07 2017-03-22 Univ Manchester Gene therapy
JOP20190245A1 (ar) 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
MA50746A (fr) 2017-10-02 2020-08-12 Denali Therapeutics Inc Protéines de fusion comprenant des enzymes d'enzymothérapie substitutive
AR116566A1 (es) 2018-10-03 2021-05-19 Novartis Ag Administración sostenida de polipéptidos similares a la angiopoyetina 3
CA3123747A1 (en) 2019-01-07 2020-07-16 Ucl Business Ltd Polymersomes functionalised with multiple ligands
US20250000999A1 (en) 2021-11-24 2025-01-02 Ucl Business Ltd Polymersomes for clearance of amyloid beta and/or tau proteins
WO2024147020A1 (en) 2023-01-06 2024-07-11 Vianautis Bio Limited Polymersomes for delivery of nucleic acid cargoes

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003102583A1 (en) * 2002-05-29 2003-12-11 Symbiontics, Inc. Targeted therapeutic proteins
WO2004108071A2 (en) * 2003-06-05 2004-12-16 Salk Institute For Biological Studies Targeting polypeptides to the central nervous system
WO2006108052A2 (en) * 2005-04-06 2006-10-12 Genzyme Corporation Peg and polysialic lysosomal enzyme conjugates via acid labile linkers for therapeutic targeting
MX2010006925A (es) * 2007-12-20 2011-05-02 Angiochem Inc Conjugados de polipeptido-acido nucleico y sus usos.
CN103665170A (zh) * 2008-12-05 2014-03-26 安吉奥开米公司 肽治疗剂轭合物及其应用
MX2011005963A (es) * 2008-12-05 2011-09-01 Angiochem Inc Conjugados de neurotensina o analogos de neurotensina y sus usos.
US20120277158A1 (en) * 2009-10-06 2012-11-01 Angiochem Inc. Compositions and methods for the transport of therapeutic agents
EP2333074A1 (en) * 2009-12-14 2011-06-15 Robert Steinfeld Substances and methods for the treatment of lysosmal storage diseases

Also Published As

Publication number Publication date
WO2013078562A3 (en) 2013-09-06
EP2785837A2 (en) 2014-10-08
JP2015500800A (ja) 2015-01-08
EP2785837A4 (en) 2015-07-01
AU2012344700A1 (en) 2014-06-19
CA2857548A1 (en) 2013-06-06
WO2013078562A2 (en) 2013-06-06
US20140335163A1 (en) 2014-11-13
RU2014126482A (ru) 2016-01-27
BR112014013250A2 (pt) 2019-09-24
CN104136606A (zh) 2014-11-05

Similar Documents

Publication Publication Date Title
HRP20190135T1 (hr) 4-imidazopiridazin-1-yl-benzamidi i 4-imidazotriazin-1-yl-benzamidi kao inhibitori btk
HK1200190A1 (zh) 靶向的酶化合物及其應用
HK1204002A1 (zh) 靶向的溶酶體酶化合物
EP2714970A4 (en) Enzyme QUANTIFICATION
IL233051A0 (en) Anti-phf-tau antibodies and uses thereof
GB201004179D0 (en) Enzyme inhibitors
GB201007384D0 (en) Enzymes
IL229844B (en) Anti-psgl-1 antibodies and their use
HK1198827A1 (zh) 抑制劑及其用途
GB201004178D0 (en) Enzyme inhibitors
GB201110783D0 (en) Methods and uses
ZA201500911B (en) Enzymes
GB201112231D0 (en) Micro-organism
GB201116774D0 (en) Uses and methods
EP2655646A4 (en) TARGETED PERHYDROLASES
GB201111775D0 (en) Compounds and uses thereof
GB201207018D0 (en) Enzymes
EP2728001A4 (en) METHOD FOR MODIFYING ENZYME FUNCTIONS AND ENZYME VARIANT THEREFOR
GB201108490D0 (en) Methods and uses
GB201105987D0 (en) Enzymes
GB201115285D0 (en) Biosensor and uses thereof
PT2734522T (pt) 4-imidazopiridazina-1-il-benzamidas e 4-imidazotriazin-1- il-benzamidas como inibidores de btk
GB201114748D0 (en) Enzyme inhibition
GB201114751D0 (en) Enzyme inhibition
GB201121726D0 (en) Compounds and uses thereof